Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients

Napolitano, Daniele; Settanni, Carlo Romano; Parisio, Laura; Orgiana, Nicoletta; Poscia, Andrea; Schiavoni, Elisa; Turchini, Laura; Cascio, Alessio Lo; Germini, Francesco; Sblendorio, Elena; Milani, Alessandra; Patteril, Christopher; Laterza, Lucrezia; Lopetuso, Loris Riccardo; Pugliese, Daniela; Papa, Alfredo; Gasbarrini, Antonio; Scaldaferri, Franco

doi:10.1007/s12664-023-01500-2

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, shorter, one-hour nurse-led infusion protocols revealed a lower incidence of infusion reactions compared to the standard two-hour procedure [ 21 ]. Napolitano et al found a noteworthy correlation between the approval rate for SC therapy and the distance from the IBD center [ 14 ]. Intriguingly, within the initially investigated range of 50 km, the distance does not seem to exert a substantial impact on the decision.…”

Section: Discussionmentioning

confidence: 99%

“…Factors such as distance from the IBD center and personal commitments influenced the approval rate for home therapy. Notably, only a quarter of patients were aware of the subcutaneous administration option for therapeutic agents [ 14 ]. In a study conducted at Nancy Hospital in France, 16.7% of vedolizumab patients and 24.5% of those treated with infliximab declined to transition from IV to SC [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Richter,

Cohen,

Kriger-Sharabi

et al. 2024

JCM

View full text Add to dashboard Cite

Biological inflammatory bowel disease (IBD) medications, once limited to intravenous (IV) administration, can now be administered both via IV and subcutaneously (SC). This study investigates patient preferences, willingness to switch from IV to SC, and associated factors. A questionnaire covering demographics, disease-related inquiries, quality of life, and IBD medication preferences was distributed via email, the Israeli Crohn’s Disease and Ulcerative Colitis Foundation, infusion centers, and clinics. From 454 IBD patients (median age: 42 years; 55.7% female), responses revealed a preference for SC every 8 weeks, which is comparable to daily oral dosing. Both options were significantly favored over IV every 8 weeks and SC every 2 weeks, with no statistically significant differences between the latter two. However, among patients who were experienced with both SC and IV administration, a clear preference for SC administration every 2 weeks over IV every 8 weeks surfaced. Among IV-treated patients, 54.5% resisted switching to SC. Key reasons for this included medical staff presence (57.7%), a fear of needles (46.4%), belief in infusion efficacy (37.1%), and longer intervals between infusions (36.1%). Findings suggest that transitioning from IV to SC treatment is challenging due to patient resistance, which is influenced by specific factors. Identifying and addressing these obstacles is crucial for optimizing IBD management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%